Please login to the form below

M3 announces further expansion into Europe and Latin America with the acquisition of Vidal Group

M3 is strengthening and growing its global operations with the acquisition of Vidal Group, a trusted provider of prescribing information and clinical decision support services to doctors and other HCPs in key markets including France, Germany, Spain and Latin America. This move complements M3’s existing business activities in Japan, the United States, United Kingdom, China, Korea and India.

Since the first publication of its pharmaceutical information encyclopaedia in 1914, the Vidal brand has gained powerful recognition amongst doctors, HCPs and the general public across French speaking countries.Additionally, Vidal’s brands such as Gelbe Liste and MMI Pharmindex in Germany and Vidal Vademecum in Spain,Central and South America, are well-renowned within their respective markets.
Vidal is recognised as the most trusted information source by physicians in France (n=388, June 2015) and has reach to over 290,000 doctors andmany other health care professionals in Europe and Latin America.
Vidal provides a very comprehensive multimedia suite of services with prescribing information and clinical decision support to enable doctors, pharmacists and other HCPs to deliver better patient care through the optimal use of medicines and therapeutics and the adoption of new advances in medical knowledge.
Through this acquisition, M3 plans to support the continued growth of Vidal’s existing services across Europe and Latin America and to expand the range of services provided to healthcare by leveraging M3’s experience and expertise in other markets including market research, digital communications, clinical trials and recruitment services.
Aki Tomaru, Board Director and CEO of M3 USA commented “The addition of the Vidal Group to M3 marks a very significant and important step for M3 in its mission to deliver trusted and high quality medical information and services in key markets across the world to drive forward innovation, improved efficiency and better outcomes in healthcare.”

About M3:
M3 operates in Asia, the US and Europe with more than 4 million physician doctor members globally via M3.com,MDLinx, Medigate, medlive.cn, M3Medical and Doctors.net.uk. Ranked 5th on Forbes’ Most Innovative Growth Companies in 2016, M3 provides a wide range of healthcare services across clinical trials, pharmaceutical marketing, research services, educational programmes, patient information and physician recruitment services.More information and contacts:For more information on the acquisition of the Vidal Group by M3 please contact Hannah Brown on +44 (0)7747273879 or hannah.brown@eu.m3.com.For more information on M3 visit http://www.m3.com or http://eu.m3.com

3rd December 2016

Share

Company Details

M3 (EU)

+44 (0)1235 828400

Contact Website

Address:
101 Park Drive
Milton Park
Milton Park
Abingdon
Oxfordshire
OX14 4RY
UK

Latest content on this profile

Learning to invest in doctors’ education
Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for more educational resources. However, the industry can find it hard to make a break from traditional methods of engaging with doctors, such as promotional communications and the traditional sales representative call to hospitals and GP surgeries.
M3 (EU)
Engaging doctors around the globe
Embedding a digital strategy as a prominent part of a pharmaceutical marketing campaign is becoming ever more important. Despite some perceived reluctance on the part of the industry, pharmaceutical companies are now exploring and exploiting a myriad of different digital channels in order to deliver content to, and engage with, their target audiences.
M3 (EU)
How do doctors spend their time online?
In our recent research piece, Doctor networks: The rules of engagement for pharma, some overarching principles for online engagement between the pharmaceutical industry and doctors were defined.
M3 (EU)
How do doctors want to engage with pharma on new products?
More than 80% of European doctors agree they are interested in staying up-to-date with new developments about pharmaceutical products. But what influences their choice of treatment and how do they prefer to receive product information?
M3 (EU)
M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia
M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a website provider for healthcare professionals in Russia.   M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 300,000+ physician members in Japan. Presence outside of Japan includes the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 6 million physicians as members across its global platforms.   This allows provision of services including marketing support, marketing research, and job placement support that leverage the platform’s powerful value as a media channel. MirVracha operates the medical professional website "МирВрача" with over 400,000 medical professional members, equivalent to roughly 60% of all physicians in Russia, and mainly provides marketing support services for pharmaceutical companies.   Since its founding by Shotaro Yamamoto in 2011, MirVracha has focused on building a quality network of healthcare professionals as well as improving content creation capabilities, and is now utilized by major Russian pharmaceutical companies to provide drug and disease information. In 2012, M3 entered into a capital and business alliance that includes the licensing of the MR-kun service, and have since developed a strong relationship with MirVracha through provision of support and know-how surrounding business launches and operations. M3 has completed the acquisition of MirVracha as a subsidiary, and will leverage its experience and know-how gained through its overseas business development in the United States, Europe, Asia, and other regions.   M3 will move forward with the full-scale development of services related to its physician platform in Russia by combining the high-quality network of physicians, medical institutions, and pharmaceutical companies that MirVracha has cultivated in Russia, with M3's expertise in operating websites and various services for healthcare professionals.
M3 (EU)
Revolutionising the Digital Content Delivery Model
Pharmaceutical industry processes don’t have to make the delivery of marketing campaigns slow and unmanageable, and thus ineffective. Changing working practices and really, truly thinking differently about how to deliver materials in a new and faster way is possible, but only if companies are ready to consider and embrace new, novel ways of working. Utilising these methods, M3 reduced a client's delivery time from 75 days to just 7.5 days
M3 (EU)